Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Helionetics/Laser Photonics

This article was originally published in The Gray Sheet

Executive Summary

Helionetics/Laser Photonics: U.S. Bankruptcy Court for the Middle District of Florida confirms a reorganization plan for diode and gas laser system manufacturer Laser Photonics under which Helionetics acquires 75% of common stock in Laser Photonics in exchange for the transfer to Laser Photonics of its 75% stake in excimer laser firm AccuLase and $1 mil. in cash. Helionetics says that Laser Photonics, which reported a 1994 loss of $600,000 on sales of $5.3 mil., will offer "laser manufacturing capabilities" that could accelerate AccuLase's commercialization of its transmyocardial revascularization and laser angioplasty products. In addition, Laser Photonics has developed a "relatively small excimer laser prototype" that could be used in "emerging technologies, such as photorefractive keratectomy," Helionetics says...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel